BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carrera AN, Grant MKO, Zordoky BN. CYP1B1 as a therapeutic target in cardio-oncology. Clin Sci (Lond) 2020;134:2897-927. [PMID: 33185690 DOI: 10.1042/CS20200310] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Sharma H, Raju B, Narendra G, Kumar M, Verma H, Sharma B, Tung GK, Kumar Jain S, Brás NF, Silakari O. In silico guided designing of optimized benzochalcones derivatives as potent CYP1B1 inhibitors: An integrated in vitro and ONIOM study. J Mol Graph Model 2023;119:108390. [PMID: 36502606 DOI: 10.1016/j.jmgm.2022.108390] [Reference Citation Analysis]
2 Bao Y, Wu S, Yang T, Wang Z, Wang Y, Jiang X, Ma H. Analysis of long non-coding RNA expression profile of bovine monocyte-macrophage infected by Mycobacterium avium subsp. paratuberculosis. BMC Genomics 2022;23:768. [PMID: 36418939 DOI: 10.1186/s12864-022-08997-5] [Reference Citation Analysis]
3 Singh RD, Avadhesh A, Sharma G, Dholariya S, Shah RB, Goyal B, Gupta SC. Potential of cytochrome P450, a family of xenobiotic metabolizing enzymes, in cancer therapy. Antioxid Redox Signal 2022. [PMID: 36242099 DOI: 10.1089/ars.2022.0116] [Reference Citation Analysis]
4 Hollis PR, Mobley RJ, Bhuju J, Abell AN, Sutter CH, Sutter TR. CYP1B1 Augments the Mesenchymal, Claudin-Low, and Chemoresistant Phenotypes of Triple-Negative Breast Cancer Cells. IJMS 2022;23:9670. [DOI: 10.3390/ijms23179670] [Reference Citation Analysis]
5 Huwait E, Ayoub M, Karim S. Investigation of the Molecular Mechanisms Underlying the Antiatherogenic Actions of Kaempferol in Human THP-1 Macrophages. Int J Mol Sci 2022;23:7461. [PMID: 35806463 DOI: 10.3390/ijms23137461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lang NN, Touyz RM. Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. Clin Sci (Lond) 2021;135:2661-3. [PMID: 34881389 DOI: 10.1042/CS20210986] [Reference Citation Analysis]
7 Lu Y, Nanayakkara G, Sun Y, Liu L, Xu K, Drummer C 4th, Shao Y, Saaoud F, Choi ET, Jiang X, Wang H, Yang X. Procaspase-1 patrolled to the nucleus of proatherogenic lipid LPC-activated human aortic endothelial cells induces ROS promoter CYP1B1 and strong inflammation. Redox Biol 2021;47:102142. [PMID: 34598017 DOI: 10.1016/j.redox.2021.102142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
8 Jiang W, Xia T, Liu C, Li J, Zhang W, Sun C. Remodeling the Epigenetic Landscape of Cancer-Application Potential of Flavonoids in the Prevention and Treatment of Cancer. Front Oncol 2021;11:705903. [PMID: 34235089 DOI: 10.3389/fonc.2021.705903] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
9 Mikstacka R, Dutkiewicz Z. New Perspectives of CYP1B1 Inhibitors in the Light of Molecular Studies. Processes 2021;9:817. [DOI: 10.3390/pr9050817] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]